Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

• UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida
• Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 11:30 AM GMT (6:30 AM ET) in London

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events . Replays will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA ^® (vutrisiran), ONPATTRO ^® (patisiran), GIVLAARI ^® (givosiran), and OXLUMO ^® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio ^® (inclisiran) and Qfitlia ^™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “ Alnylam P ⁵ x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam , or on LinkedIn , Facebook , or Instagram .

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104566593/en/